Key Takeaways:
Insilico Medicine dosed the first patient with Rentosertib in a 320-patient Phase III trial, the furthest any generative AI-discovered drug has advanced in human testing.
The Hong Kong-listed company (03696.HK) said the first patient received the drug at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its first participant the same day. "TNIK, the target driven by AI, had never previously been linked to fibrosis," Professor Zuojun Xu of Peking Union Medical College Hospital, the study's leading principal investigator, said. "From initiating Phase III to obtaining final regulatory approval, it will take three to four years under favorable conditions."
The trial, GENESIS-IPF-3 (NCT07687459, CTR20262475), is a 52-week randomized, double-blind, placebo-controlled study across 47 centers in China. The primary endpoint is the annual rate of decline in forced vital capacity (FVC), a standard measure of lung function; the key secondary endpoint is time to first disease progression event. Rentosertib is a small molecule targeting TNIK, a protein whose activation drives pathological fibrosis in the lungs. The U.S. Food and Drug Administration granted it Orphan Drug Designation for IPF in February 2023.
Idiopathic pulmonary fibrosis affects roughly 5 million people worldwide and carries a median survival of three to four years. Approved antifibrotic drugs slow progression but do not stop or reverse it. Insilico's Phase IIa data, published in Nature Medicine in 2025, showed a dose-dependent efficacy trend over 12 weeks.
Separately, Citi Research said analysis of Rentosertib provides the first direct clinical biomarker evidence of potential biological-age reversal across six independently developed aging clocks. The bank maintained Insilico as its top pick in the AI drug-discovery subsector. The underlying study, published in Nature Biotechnology, analyzed 42 patients over 12 weeks and found those taking the drug scored biologically three to four years younger than placebo recipients, with one case showing six years. Insilico founder and co-CEO Alex Zhavoronkov called the finding "a bonus for disease treatment" and cautioned that "we don't know what that means yet."
The limitations are material. All participants had IPF, which itself alters many of the proteins used to measure biological aging, so improvements in lung disease may explain the protein changes. The results rest on blood protein patterns, not on demonstrated gains in lifespan or healthspan. Citi's own survey of 50 U.S. R&D executives found only 10 percent expect meaningful AI impact on Phase III trials, against 70 percent who expect the largest gains in target identification.
Short selling in 03696.HK totaled $54.37 million as of the Sept. 9 close, equal to 4.74 percent of turnover, according to AASTOCKS data. The stock rose 1.2 percent, or HK$0.65, on the session. The positioning reflects the binary nature of the catalyst: a Phase III readout is years away, and the trial's 52-week treatment window means the primary endpoint will not be measured until 2027 at the earliest.
The commercial picture is stronger than the clinical timeline. Insilico reported roughly $106 million in first-half 2026 revenue, up 287 percent year over year, and its first profitable half-year since listing on Dec. 30, 2025, with adjusted net profit above $51 million. Announced 2026 deal value reached about $7.3 billion, lifting cumulative collaboration value since 2021 to roughly $11 billion, across partners including Eli Lilly, Servier, Takeda and SK Biopharmaceuticals. The company nominated nine development candidates in the first nine months of 2026.
For holders, the dosing milestone moves Rentosertib from a published Phase IIa result into a registrational study, but it does not de-risk the asset — the 320-patient enrollment across 47 centers is the number to track, and full enrollment is the next visible checkpoint. Investors will watch for enrollment updates and any interim data disclosure, with the primary FVC endpoint readout not expected before 2027.
This article is for informational purposes only and does not constitute investment advice.
